Daniel Müller

Title: **Daniel Müller: Innovator in Microfluidics from Rotkreuz, CH**

Introduction

Daniel Müller is an accomplished inventor based in Rotkreuz, Switzerland, renowned for his contributions to the field of microfluidics. With a focus on enhancing laboratory techniques, his work is pivotal in advancing the detection and analysis of nucleic acids, which are essential in various biomedical applications.

Latest Patents

Müller holds a patent for a "Sealable microfluidic chip for thermocycling." This innovative technology addresses the need for reversible sealing of microfluidic chips used in the thermal incubation of aqueous samples suspected of containing target nucleic acids. The patent describes a microfluidic chip featuring a flow channel and multiple reaction compartments, allowing the introduction of samples and a displacement fluid through a sealable inlet port. The sealing agent utilized has a melting point above room temperature, ensuring effective thermal management during experiments.

Career Highlights

Daniel Müller is associated with Roche Molecular Systems, Inc., a prominent company in molecular diagnostics. His role within the company allows him to contribute significantly to the development of cutting-edge technologies that facilitate groundbreaking research and diagnostic solutions. Müller's innovative mindset and technical expertise set him apart as a valuable asset to his team.

Collaborations

Throughout his career, Müller has collaborated with notable professionals, including Michael Glauser and Michael Zeder. These partnerships enhance the interdisciplinary nature of his work, fostering an environment of innovation and collective growth within the field of molecular diagnostics.

Conclusion

Daniel Müller stands as a noteworthy inventor in the realm of microfluidics, with a patent that showcases his ingenuity and dedication to advancing scientific research. His work at Roche Molecular Systems, Inc. and collaborations with fellow innovators signify his commitment to improving diagnostic technologies, ultimately benefiting the medical community and society at large.